Introduction
============

Congenital obstructive nephropathy (CON) is a main cause of kidney insufficiency in child and infant ([@b1-mmr-18-03-2651]). It is associated with various diseases, such as prune belly syndrome ([@b2-mmr-18-03-2651]). As a result, CON generates a huge social burden especially in the morbidity and mortality ([@b2-mmr-18-03-2651]). The different challenges associated with CON in areas like diagnose and therapy highlight the importance of the molecular mechanism of CON ([@b3-mmr-18-03-2651]). Thus, the emerging theories of the biology of CON suggest new targets for therapeutic interventions ([@b4-mmr-18-03-2651]).

Identification of novel biomarkers provides prognostic value for this process remains a major goal in the study of kidney disease ([@b5-mmr-18-03-2651]). In renal and urinary tract, previous study showed that disruption of *angiotensin type 2 receptor* (*AGTR2*) induced a huge scale of anomaly ([@b6-mmr-18-03-2651]). Meanwhile, the *Monocyte chemotactic protein 1* (*MCP-1*) as well as the *Epidermal growth factor* (*EGF*) seem to be involved in the pathogenesis of tubulointerstitial damage of CON, and their urine excretion may serve as a powerful prognostic marker for this form renal disease ([@b7-mmr-18-03-2651]). Not only gene, but also pathways enriched by differentially expressed genes (DEGs) are closed related with CON. Previous study demonstrated that TGF-β signaling pathway plays an important role in regulating kidney injury process following by obstruction ([@b8-mmr-18-03-2651]). In a rat model, Hermens *et al* ([@b9-mmr-18-03-2651]) show that there is an age-dependent role of Wnt signaling pathway in the pathophysiology of CON. Despite of revealing the potential genes or pathways, understanding the molecular mechanism of CON also brings a breakthrough for the novel treatment of CON ([@b10-mmr-18-03-2651]). The development of biomarkers contribute to molecular therapies of CON ([@b11-mmr-18-03-2651]). However, the molecular mechanisms underlying these histologic changes are still poorly defined.

To better understand the pathophysiology of CON, Brian Becknell and his colleagues evaluated the global transcription in kidneys with graded hydronephrosis in the megabladder (mgb2/2) mouse ([@b12-mmr-18-03-2651]). Based on normal, mild, moderate, and severe mouse models, they prove that the development of progressive hydronephrosis can result in renal adaptation, including significant changes in the morphology and potential functionality of the renal urothelium. However, the co-regulated gene in all models, transcription factor (TF) associated with DEGs, gene expression in severe disease status, as well as the potential chemicals for CON treatment are still unclear. In the current study, a bioinformatics research was designed based on the gene expression profile provided by Becknell *et al* ([@b12-mmr-18-03-2651]). Then, investigations of DEGs, function and pathway enrichment, protein-protein interaction network (PPI) analyses, as well as TF-target gene regulatory network were performed in all disease status. Furthermore, the chemical-gene interaction network in severe models were also investigated. We aimed to explore the potential pathoenesis of CON and provided information about novel gene targets, as well as chemicals for CON treatment.

Materials and methods
=====================

### Microarray data

Expression data of GSE48041 ([@b12-mmr-18-03-2651]), sequenced on the platform of GPL10787 Agilent-028005 SurePrint G3 Mouse GE 8×60K Microarray, were obtained from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)). A total of 24 kidney tissue samples from control and megabladder (mgb−/−) mouse aged 23--30 days were included in this dataset, and hydronephrosis was induced by renal ultrasound as previously reported ([@b13-mmr-18-03-2651]). According to the hydronephrosis degrees ([www.sfu-urology.org/sfu_hydrone_grading.cfm](www.sfu-urology.org/sfu_hydrone_grading.cfm)), animals were divided into 4 groups: Control (n=6), mild (n=7), moderate (n=5) and severe (n=6) according to their disease stages.

### Data preprocessing

The preprocessing were performed based on robust multi-array average (RMA) method ([@b14-mmr-18-03-2651]) in Affy package ([@b15-mmr-18-03-2651]) in R (v.3.10.3, [bioconductor.org/biocLite.R](bioconductor.org/biocLite.R)). Contents of processing included background correct microarray expression intensities, normalize the expression within each array, and expression calculation. The probe ID was convert to the gene symbol based on the chip platform annotation files.

### DEGs analysis

Classical Bayes method in Linear Models for Microarray Data (limma) package ([@b16-mmr-18-03-2651]) of R was used to reveal DEGs by comparing expression value among samples from three comparisons: Mild vs. control, moderate vs. control, and severe vs. control. P-value \<0.05 and \|log~2~ log fold change (FC)\|≥1 were selected as the cut-off criteria for DEG screening.

### VennPlot analysis of DEGs

VENNY (v.2.1) ([@b17-mmr-18-03-2651]) is an online tool used for Venn diagram analysis based on gene expression value. The number of up-regulated, down-regulated, and contra-regulated genes can be marked by VennPlex. In the present study, VennPlex software was used to investigate the difference of DEGs among 3 comparative groups. Then, the co-regulated DEGs (Set 1) and severe group DEGs (Set 2) were selected for further investigation.

### Enrichment analysis of DEGs

The Database for Annotation, Visualization, and Integrated Discovery (DAVID; v.6.8) ([@b18-mmr-18-03-2651]) provides a synthetic set of functional annotation tools for users for revealing the biological significances among huge scale of genes. Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis were performed using DAVID online tool ([@b19-mmr-18-03-2651]). GO functional categories including molecular function (MF), biological process (BP), and cellular component (CC) ([@b20-mmr-18-03-2651]). In the present study, GO functions assembled by DEGs in severe group, as well as KEGG pathways enriched by the co-regulated DEGs were investigated. P-value \<0.05 and enriched gene numbers (count) ≥2 were considered as cut-off values.

### PPI network investigation

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; v.10.0) is an online tool for the predication of PPI based on a large scale of biological database ([@b21-mmr-18-03-2651]). In the present study, STRING was used to predict the interaction relations between DEGs corresponding coding proteins. PPI were revealed based on the STRING database with score (median confidence)=0.4, and nodes represent DEGs in the PPI interaction. The degree was defined as the number of the connections for the target proteins. Cytoscape software (v.3.2.0) ([@b22-mmr-18-03-2651],[@b23-mmr-18-03-2651]) was used for the visualization of PPI network obtained above. Then, the CytoNCA software (v.2.1.6, [apps.cytoscape.org/apps/cytonca](apps.cytoscape.org/apps/cytonca)) ([@b24-mmr-18-03-2651]) was used for the nodes topological analysis (Parameter: Without weight). Furthermore, the sub-networks with score \>4.5 were identified by MOCDE (v.1.4.2; [apps.cytoscape.org/apps/MCODE](apps.cytoscape.org/apps/MCODE)) ([@b23-mmr-18-03-2651]) plugin in Cytoscape software.

### TF-target gene regulatory network construction

TF is an important class of participators in the regulation of gene expression. Analysis of TF binding sites is of great significance for the study of gene regulation system. In the current research, the TFs-co-regulated DEGs network was constructed with iRegulon ([@b25-mmr-18-03-2651]) (v.1.3, [apps.cytoscape.org/apps/iRegulon](apps.cytoscape.org/apps/iRegulon)). The Parameters of this analysis were set as: Minimum identity between orthologous genes=0.05, and maximum false discovery rate (FDR) on motif similarity=0.001. TF-target gene relations with normalized enrichment score (NES) \>4 were considered as the meaningful results.

### Chemical-DEGs interaction network construction

Comparative Toxicogenomics Database (CTD) provides relationships, such as chemical-gene/protein interactions, chemical-disease as well as gene-disease ([@b26-mmr-18-03-2651]). Relationship between disease (Nephrosis, congenital) associated chemical-gene or interactions was revealed by CDT. Then Chemical-DEGs interaction network was constructed by Cytoscape software.

Results
=======

### DEGs investigation in mild, moderate and severe groups

Considering a huge amount of calculation in gene expression profile, the original data was analyzed and filtered. The results revealed that totally 220 up-regulated DEGs and 225 down-regulated DEGs were obtained in the mild group. In the moderate group, there were 375 up-regulated DEGs and 142 down-regulated DEGs screened out. Furthermore, a total of 484 up-regulated DEGs and 280 down-regulated DEGs uncovered in the severe group.

### VennPlot analysis

VennPlot for DEGs in the mild, moderate, and severe groups were investigated in the present study ([Fig. 1](#f1-mmr-18-03-2651){ref-type="fig"}). The results revealed 187 co-regulated DEGs in Set 1, including 87 up-regulated DEGs and 100 down-regulated DEGs. In Set 1, *Serpina6, Hpd*, and *Nr4a1* were the 3 most outstanding up-regulated genes, while *Proz, 4122401K19Rik*, and *Nudt19* were the 3 most outstanding down-regulated genes. Meanwhile, there were 139 DEGs in Set 2, including 121 up-regulated DEGs and 18 down-regulated DEGs. In Set 2, *Sprr2f, Lcn2* and *Saa2* were the 3 most outstanding up-regulated gene, while *Symbol, Vps8* and *Ang2* were the 3 most down-regulated gene.

### KEGG and GO enrichment analysis

The KEGG analysis of DEGs in Set 1 showed that a total of 16 pathways were significantly enriched ([Table I](#tI-mmr-18-03-2651){ref-type="table"}). The up-regulated DEGs were mostly enriched in TNF signaling pathway (mmu04668, P=3.59×10^−4^), while the down-regulated DEGs were mainly assembled in Retinol metabolism (mmu00830, P=1.36×10^−7^). Among these pathways, Chemical carcinogenesis (mmu05204, Gene: *CBR1, UGT2B38, GSTA2, UGT2B37* and *UGT2B36*) was the common pathway in all 3 group of Set 1. The detail pathway map of Chemical carcinogenesis was showed in [Fig. 2](#f2-mmr-18-03-2651){ref-type="fig"}.

GO functional analysis was performed in the severe group DEGs. With count number \>10, the top 10 of BP, CC, and MF functions were revealed, respectively. The DEGs in the severe group was mainly assembled in functions like inflammatory response (BP, GO: 0006954, P=1.43×10^−3^), cellular response to interleukin-1 (BP, GO: 0071347, P=8.87×10^−3^), cellular response to tumor necrosis (BP, GO: 0071356, P=6.34×10^−4^), extracellular region (CC, GO: 0005576, P=3.53×10^−7^), and cytokine activity (MF, GO: 0005125, P=7.63×10^−5^). The detail information was showed in [Fig. 3](#f3-mmr-18-03-2651){ref-type="fig"}.

### PPI network and modules analysis

To dig out the potential interactions of the DEGs, PPI network and related modules were constructed based on the protein interactions of DEGs. A total of 102 nodes (*Jun, Fos, Ptgs2, Ugt2b37, Junb, Atf3, Cyp4a12a, Adh1, Ugt2b5, Egr1*, etc.) and 320 interactions were identified in the PPI network of Set 1. With score \>4.5, 2 modules were further obtained from the Set 1 PPI network. There were 13 nodes (*Jun, Fos, Ptgs2, Junb, Atf3, Egr1, Dusp1, Nr4a1, Zfp36, Btg2*, etc.) and 60 interactions in module a (score=10), while 8 nodes (*Ugt2b5, Cyp2j13, Acsm3, Cyp4a12b, Cyp4a14, Cyp4b1 Slc22a30* and *Slc7a13*) and 20 interactions contained in module b (score=5.714) ([Fig. 4](#f4-mmr-18-03-2651){ref-type="fig"}). Furthermore, there were a total of 73 nodes (*Ccl2, Timp1, Acta2, Spp1, Actg2, Thbs1, Edn1, Aldh1a1, Mmp3, Aldh1a7*, etc.) and 143 interactions included in the PPI network of Set 2. With score \>4.5, one module was further obtained from the Set 2 PPI network. A total of 5 nodes (*Aldh1a1, Aldh1a7, Aifm3, Hbb-b1 and Acad9*) and 9 interactions were revealed in the module of Set 2 ([Fig. 5](#f5-mmr-18-03-2651){ref-type="fig"}).

### TF-target gene regulatory network analysis

By using the iRegulon software, 2 TFs (*Polr2a* and *Srf*) were obtained from the Set 1 PPI network. To further investigate the relationship between TFs and their target genes, the TF-target gene network was visualized by cytoscape software. With NES \>4, the results showed that there were totally 52 regulatory relations contained in this network. Some genes like *FOS* were co-regulated by both *Polr2a* and *Srf*. The detail information was showed in [Fig. 6](#f6-mmr-18-03-2651){ref-type="fig"}.

### Chemical-gene interaction network analysis

The present study revealed totally 12012 chemical-gene interactions related to Nephrosis or congenital. Among these interactions, totally 60 interactions were matched with the 139 DEGs in Set 2. The results showed that Cyclosporine was the most important chemical that target with either the most number of up-regulated or down-regulated DEGs in Set 2. Detailed information was listed in [Table II](#tII-mmr-18-03-2651){ref-type="table"}.

Discussion
==========

CON is the leading cause of chronic kidney disease in child. However, the molecular mechanisms underlying disease progression are still poorly defined. To reveal the potential genes or pathways associated with CON, the present bioinformatics study was performed on mild, moderate, and severe CONs. The results showed that totally 187 and 139 co-regulated DEGs were obtained in Set 1 and Set 2, respectively. KEGG analysis for Set 1 showed that DEGs were mainly enriched in pathways like chemical carcinogenesis. Meanwhile, the GO analysis for Set 2 showed that DEGs were mainly assembled in functions like cellular response to interleukin-1 and cellular response to tumor necrosis. Two modules in Set 1 and one module in Set 2 were revealed based on PPI network analysis. Furthermore, the genes like *FOS* were co-regulated by TFs like *Polr2a* and *Srf*. Cyclosporine was the most important chemical that target with DEGs in Set 2.

Based on the Set 1 (including all disease status like mild, moderate and severe), KEGG pathway analysis, PPI network analysis, and TF-target investigation were carried out in this study to provide a potential mechanism understanding for the process of CON. Chemical carcinogenesis is a process that the cells need genetic and epigenetic variations based on elements including oncogenes and tumor suppressors ([@b27-mmr-18-03-2651],[@b28-mmr-18-03-2651]). *Carbonyl reductase 1* (*CBR1*) metabolized by the body many toxic environmental quinones and pharmacological relevant substrates, such as the anticancer doxorubicin ([@b27-mmr-18-03-2651]). Previous study has shown that *CBR1* is vital for the cell protection in functions like oxidative stress and apoptosis ([@b29-mmr-18-03-2651]). Pathway analysis showed that the chemical carcinogenesis was the common pathway enriched by both up- and down-regulated DEGs (especially *CBR1* in Set 1). Thus, we speculated that DEGs like CBR1 in chemical carcinogenesis pathway might be the potential pathogenesis of CON. However, the related study associated with chemical carcinogenesis pathway about *CBR1* and *CON* is very rare. Furthermore, c-Fos (*FOS*) gene has been considered as the regulators of cell proliferation, differentiation, transformation, and apoptotic cell death ([@b30-mmr-18-03-2651],[@b31-mmr-18-03-2651]). Otsuka *et al* ([@b32-mmr-18-03-2651]) indicates that the expression of *FOS* is potentially an early indicator of late radiation damage to the kidney. In rats model, previous study indicated that the renoprotective effects of drugs partly through inhibiting the upregulation of *FOS* mRNA and protein in renal cortices ([@b33-mmr-18-03-2651]). In the present study, the PPI network analysis showed tha*t FOS* was one of the most outstanding DEGs in Set 1. Interestingly, the TF-target gene network in this study showed that *FOS* was the co-target gene of *Polr2a* and *Srf*. Thus, we speculated that DEGs like *FOS* might play an important role in the process of CON via TFs like *Polr2a* and *Srf*. However, the related study associated with *FOS* and CON is very rare. Thus, an additional research with a wide scale of gene expression analysis is necessary to confirm this speculation.

Based on Set 2 (only severe group), GO function analysis and chemical-gene interaction network investigation in this study were performed and intended to provide a potential therapy strategy for CON. Interleukin-1 family plays a vital role in the immune and inflammatory responses regulation ([@b34-mmr-18-03-2651]). Previous study showed that the protective effect of interleukin-1 in renal injury might be induced by reducing the induction of the nuclear factors ([@b35-mmr-18-03-2651]). Actually, Pindjakova *et al* ([@b36-mmr-18-03-2651]) indicate that the production of interleukin-1 based on the resident dendritic cells enhances the situation of acute kidney injury. Moreover, tumor necrosis factor (TNF) is a superfamily of cytokines that can lead to cell death, and it is a potent pyrogen that can be caused by stimulation of interleukin-1 secretion ([@b37-mmr-18-03-2651]). Meldrum *et al* ([@b38-mmr-18-03-2651]) prove that TNF-α mediates renal tubular cell apoptosis in the process of obstructive uropathy. Recent study indicates that the production of TNF-α by macrophages take part in the progression of renal injury ([@b39-mmr-18-03-2651]). Actually, interleukin-1 and TNF-α gene polymorphism are associated with the susceptibility, disease activity and long-term outcome in human nephropathy ([@b40-mmr-18-03-2651]). In the current research, the results of GO analysis showed that cellular response to interleukin-1 and cellular response to tumor necrosis is two of most outstanding function assembled by DEGs. Thus, we speculated that these two functions might be vital for the process of severe CON. The deteriorated or even canceration might take place in severe CON, which needed an early therapy intervention. Furthermore, cyclosporine, also spelled ciclosporin or cyclosporin, is an immunosuppressant medication and natural product ([@b41-mmr-18-03-2651]). As an immunosuppressant with therapeutic indications in various immunological diseases, the use of cyclosporine is reported to be associated with chronic nephropathy ([@b42-mmr-18-03-2651]). In the present study, cyclosporine was the most outstanding chemical associated with DEGs identified in severe CON. Thus, cyclosporine might still be the preferences for the therapy of CON. However, due to the negative effects of cyclosporine in CON clinical treatment, a more effective drug with less adverse reaction is needed.

However, there were still some limitations in this study. First, findings in the present study were all analyzed by bioinformatics methods, and experimental validations were deficient. Second, parameters used in *in silico* analyses were set manually, and some results might be missed or overemphasized. Therefore, further experimental validations in both *in vivo* and *in vitro* were required in the future.

In conclusion, the DEGs like *CBR1* and *FOS*, TFs like *Polr2a* and *Srf*, as well as pathways like chemical carcinogenesis might play important roles in the process of CON. Interleukin-1 and tumor necrosis function were associated with the deteriorate of CON, and might be novel targets for CON treatment. Furthermore, a more effective drug with less adverse reaction for severe CON is needed.
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![PPI network and modules of common DEGs in the mild, moderate and severe group. Red circles represent the upregulated genes and purple diamonds represent the downregulated genes. A bigger node indicates a higher degree. PPI, protein-protein interaction; DEGS, differentially expressed genes.](MMR-18-03-2651-g03){#f4-mmr-18-03-2651}
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![TF-target gene regulatory network. Green hexagons represent TFs; red circles represent the upregulated genes; purple diamonds represent the downregulated genes; and arrows indicate the direction of regulation. TF, transcription factor.](MMR-18-03-2651-g05){#f6-mmr-18-03-2651}

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for common DEGs in the mild, moderate and severe groups.

  Regulation   Pathway ID   Pathway name                                   Count   P-value
  ------------ ------------ ---------------------------------------------- ------- -----------
  ALL          mmu00980     Metabolism of xenobiotics by cytochrome P450   9       2.84×10-7
               mmu00830     Retinol metabolism                             10      3.16×10-7
               mmu05204     Chemical carcinogenesis                        10      4.21×10-7
               mmu00982     Drug metabolism-cytochrome P450                8       5.09×10-6
               mmu00053     Ascorbate and aldarate metabolism              5       1.64×10-4
               mmu01100     Metabolic pathways                             27      4.04×10-4
               mmu00040     Pentose and glucuronate interconversions       5       5.13×10-4
               mmu00860     Porphyrin and chlorophyll metabolism           5       8.48×10-4
               mmu00983     Drug metabolism-other enzymes                  5       1.93×10-3
               mmu00140     Steroid hormone biosynthesis                   6       2.12×10-3
               mmu00590     Arachidonic acid metabolism                    6       2.34×10-3
               mmu04668     TNF signaling pathway                          6       5.60×10-3
               mmu04976     Bile secretion                                 5       6.42×10-3
               mmu00071     Fatty acid degradation                         4       1.45×10-2
               mmu05140     Leishmaniasis                                  4       2.93×10-2
               mmu04610     Complement and coagulation cascades            4       4.53×10-2
  UP           mmu04668     TNF signaling pathway                          6       3.59×10-4
               mmu05140     Leishmaniasis                                  4       5.65×10-3
               mmu04010     MAPK signaling pathway                         6       1.39×10-2
               mmu05204     Chemical carcinogenesis                        4       1.52×10-2
               mmu05152     Tuberculosis                                   5       1.74×10-2
               mmu05166     HTLV--I infection                              6       2.01×10-2
               mmu05142     Chagas disease (American trypanosomiasis)      4       2.06×10-2
               mmu04978     Mineral absorption                             3       2.26×10-2
  DOWN         mmu00830     Retinol metabolism                             8       1.36×10-7
               mmu00053     Ascorbate and aldarate metabolism              5       6.48×10-6
               mmu00980     Metabolism of xenobiotics by cytochrome P450   6       1.03×10-5
               mmu00982     Drug metabolism-cytochrome P450                6       1.20×10-5
               mmu01100     Metabolic pathways                             18      1.73×10-5
               mmu00040     Pentose and glucuronate interconversions       5       2.11×10-5
               mmu00860     Porphyrin and chlorophyll metabolism           5       3.57×10-5
               mmu00140     Steroid hormone biosynthesis                   6       4.64×10-5
               mmu05204     Chemical carcinogenesis                        6       6.07×10-5
               mmu00983     Drug metabolism-other enzymes                  5       8.52×10-5
               mmu04146     Peroxisome                                     4       6.63×10-3
               mmu00071     Fatty acid degradation                         3       2.17×10-2

Count values indicate the number of genes enriched in a pathway. P\<0.05 and the gene number (count) ≥2 were considered the threshold values for significant differences. DEGs, differentially expressed genes; UP, upregulated; DOWN, downregulated; ALL, up- and downregulated.

###### 

Chemical-target gene interaction network.

  Gene      Chemical name   Description   Gene     Chemical name   Description   Gene        Chemical name   Description
  --------- --------------- ------------- -------- --------------- ------------- ----------- --------------- -------------
  ACTA2     Cyclosporine    UP            EREG     Cyclosporine    UP            RGS16       Cyclosporine    UP
  ACTG2     Cyclosporine    UP            FGB      Cyclosporine    UP            RHOU        Cyclosporine    UP
  AIFM3     Cyclosporine    DOWN          FOXA1    Cyclosporine    UP            S100A6      Cyclosporine    UP
  ALDH1A1   Cyclosporine    UP            FOXQ1    Cyclosporine    UP            SAA2        Cyclosporine    UP
  APOC2     Cyclosporine    UP            GDF15    Cyclosporine    UP            SAMD5       Cyclosporine    UP
  BCAS1     Cyclosporine    UP            GPR87    Cyclosporine    UP            SDC1        Cyclosporine    UP
  BCL2L14   Cyclosporine    UP            IGFBP1   Cyclosporine    UP            SERPINA3N   Cyclosporine    UP
  CAPG      Cyclosporine    UP            IGFBP6   Cyclosporine    UP            SLC16A3     Cyclosporine    UP
  CCL2      Cyclosporine    UP            ITGA11   Cyclosporine    UP            SLC17A3     Cyclosporine    DOWN
  CCL6      Cyclosporine    UP            LCN2     Cyclosporine    UP            SLC39A4     Cyclosporine    UP
  CD14      Cyclosporine    UP            LOX      Cyclosporine    UP            SPP1        Cyclosporine    UP
  CES1E     Cyclosporine    DOWN          LTBP2    Cyclosporine    UP            TACSTD2     Cyclosporine    UP
  CLDN4     Cyclosporine    UP            MDK      Cyclosporine    DOWN          TAGLN       Cyclosporine    UP
  CNN1      Cyclosporine    UP            MFAP5    Cyclosporine    UP            TGFB3       Cyclosporine    UP
  COL27A1   Cyclosporine    DOWN          MGST2    Cyclosporine    UP            THBS1       Cyclosporine    UP
  CP        Cyclosporine    UP            MMP3     Cyclosporine    UP            TIMP1       Cyclosporine    UP
  CPE       Cyclosporine    UP            MMP7     Cyclosporine    UP            TRPV6       Cyclosporine    UP
  CTSE      Cyclosporine    UP            OSMR     Cyclosporine    UP            TUBB2B      Cyclosporine    UP
  EDN1      Cyclosporine    UP            PAK3     Cyclosporine    UP            UCHL1       Cyclosporine    UP
  ENTPD3    Azathioprine    UP            PLAUR    Cyclosporine    UP            UPK3A       Cyclosporine    UP

UP, upregulated; DOWN, downregulated.
